

MINUTES

Utah Department of Health Drug Utilization Review Board

Thursday, January 12th, 2017 7:15 a.m. to 8:30 a.m. Cannon Health Building Room 125

Board Members Present:

Ben Berrett, Pharm.D.

Neal Catalano, Pharm.D.

Sharon Weinstein, M.D.

Kim Michelson, D.D.S.

Katherine Smith, Pharm.D.

Jennifer Brinton, M.D., Board Chair

Holly Gurgle, Pharm.D.

Steve Lore, M.D.

Kumar Shah, M.Sc., P.Eng.

Michael Symond, M.D.

Keith Tolman, M.D.

Board Members Excused:

Aesha Drozdowski, Pharm.D.

Dept. of Health/Div. of Health Care Financing Staff Present:

Chad Hope, Pharm D

Bryan Larson, Pharm.D

Susan Siegfreid, M.D

Heather Santacruz, R.N.

Robyn Seely, Pharm D.

Megan Schlappi, C.Ph.T.

Merelynn Berrett, R.N

Alyssa Pitts, R.N.

Other Individuals Present:

Joanita Lake, U of U*
Valeria Gonzaels, U of U*
Tony Rhodes, UofU*
Cody Ball, Select Health
John Vu, Molina
Don McCaffery, Vertex
Dane West
Eric Cannon, Select Health

Lori Howarth, Bayer Christopher Valentine, Health Choice Utah

Trina Ballard, Bayer Cody Ball, Select Health

Robert Nohavec, UofU Health Plans Charissa Anne, Johnson & Johnson

Matt Mitchell, Select Health Melanie Bacher, Molina

Hal Goock, Molina Jennifer Lauper, Bristol Myers Squibb

Linda Craig, Amgen Laura Britton, Healthy U

*UofU = University of Utah

Meeting conducted by: Jennifer Brinton, M.D.

- 1. **Welcome & Housekeeping:** Jennifer Brinton, M.D. opened the meeting and reminded everyone to sign the rosters.
- 2. **Review and Approval of December Minutes:** Kumar Shah, M.Sc., P.Eng. made a motion to approve the minutes from December. Neal Catalano, Pharm.D. seconded the motion. Ben Berrett abstained, otherwise unanimous (10-0-1).

- 3. Accountable Care Organization Update: Report on Methodologies for Preferred Drug List Development

 - **b.** Healthy U.....Laura Britton, Pharm.D., Director of Pharmacy Services
 - c. Molina......Jon Vu Pharm.D., Director, Health Plan Pharmacy Services
 - d. Select Health......Cody Ball, Pharm.D., Clinical Pharmacy Coordinator
- 4. Oral and Implantable Buprenorphine Products for the Treatment of Opiate Abuse (Probuphine, Bunavail, Suboxone, Zubsolv & generic), Discussion Continued from December 2016 DURB meeting
 - **a.** Robyn Seely, Pharm.D., presented several drafts of potential prior authorization (PA) criteria, as requested by the Board at the previous meeting.

b. Board Discussion:

- 1. Keith Tolman, M.D. and Mike Symond, M.D., mentioned including or excluding concomitant benzodiazepines in the PA criteria.
- 2. Steve Lore, M.D., asked for confirmation of a point in clinical guidelines regarding induction of therapy with single-agent buprenorphine.
- 3. The length of treatment was comprehensively discussed.
- 4. Tapering of therapy, with or without associated dose limits at different taper steps, were discussed. Should patients have to taper all the way off medication, or to lowest possible dose?
- 5. The role of Methadone Clinics in comprehensive treatment was mentioned.
- 6. The usual 9-month review of this criteria may not allow sufficient time for meaningful data to be collected. A review in greater-than-or-equal-to 18 months was suggested.

c. Public Comment:

- 1. Chris Valentine M.D......Medical Director, Health Choice
 - a. Spoke as a Suboxone provider, not as Health Choice's Medical Director, in support of tapering.
- - a. Mentioned Lexi-Comp recommended Subutex® dosing

d. Continued Board Discussion:

- 1. New criteria was adapted. Steve Lore, M.D. made a motion to approve the new criteria. Keith Tolman, M.D. seconded the motion. Unanimous (11-0-0).
- 5. **Long Acting Blood Factors:** not discussed due to time constraints, and will be discussed in February.
- 6. Public Meeting Adjourned
- 7. The next meeting is scheduled for February 9th, 2017.

Audio recordings of DUR meetings are available online at: https://medicaid.utah.gov/pharmacy/drug-utilization-review-board?p=DUR Board Audio Recordings/